Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4135-4141

  Weber, Ann E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXYLGLYCLPYRROLIDIDE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP 728; ENZYME INHIBITOR; FE 999011; FE 9990111; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLYCINE DERIVATIVE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; ISOLEUCYLTHIAZOLIDIDE; PIOGLITAZONE; PYRROLIDINE DERIVATIVE; SARCOSINE; SULFONAMIDE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; XANTHINE DERIVATIVE;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FOOD INTAKE; HUMAN; HYPOGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET BETA CELL; PRURITUS; SHORT SURVEY; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, CD26; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3843072211     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030628v     Document Type: Short Survey

References (85)

1. Creutzfeldt, W. The Incretin Concept Today. Diabetologia 1979, 16, 75-85.
2. Knudsen, L. B. Glucagon-like Peptide-1: The Basis of New Class of Treatment for Type 2 Diabetes. J. Med. Chem. 2004, 47, 4128-4134.
3. (a) Mentlein, R.; Ballwitz, B.; Schmidt, W. E. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993, 214, 829-835.
4. (b) Kieffer, T. J.; McIntosh, C. H. S.; Pederson, T. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrine 1995, 136, 3585-3596.
5. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44, 1126-1131.
6. (a) He, X. S.; Zhang, X.; Zhao, H.; DeSimone, R.; Thurkauf, A. 1-Benzylimidazole derivatives. U.S. 6,482,844, 2002.
7. (b) Desimone, R. W.; Hutchison, A. Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics. WO 00/59887, October 12, 2000.
8. (c) Teng, M.; Truesdale, L.; Bhumralkar, D.; Kiel, D.; Johnson, M. D.; Thomas, C.; Jørgensen, A.; Madsen, P.; Olesen, P. Non-peptide GLP-1 Agonists. WO 00/42026, July 20, 2000.
9. (a) Holst, J. J.; Deacon, C. F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998, 47, 1663-1670.
10. (b) Augustyns, K.; Bal, G.; Thonus, G.; Belyaev, A.; Zhang, X. M.; Bollaert, W.; Lambeir, A. M.; Durinx, C.; Goossens, F.; Haemers, A. The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr. Med. Chem. 1999, 6, 311-327.
11. (c) Villhauer, E. B.; Coppola, G. M.; Hughes, T. E. DPP-IV inhibition and therapeutic potential. Annu. Rep. Med. Chem. 2001, 36, 191-200.
12. (d) Drucker, D. J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Invest. Drugs 2003, 12, 87-100.
13. (e) Wiedeman, P. E.; Trevillyan, J. M. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr. Opin. Invest. Drugs 2003, 4, 412-420.
14. (f) Augustyns, K.; Van der Veken, P.; Senten, K.; Haemers, A. Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 2003, 13, 499-510.
15. (a) De Meester, I.; Korom, S.; Van Damme, J.; Scharpé, S. CD26, let it cut or cut it down. Immunol. Today 1999, 20, 367-375.
16. (b) Hildebrandt, M.; Reutter, W.; Arck, P.; Rose, M.; Klapp, B. F. A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defense. Clin. Sci. 2000, 99, 93-104.
17. (c) Boonacker, E.; Van Noorden, C. J. F. The multifunctional or moonlighting protein CD26/DPPIV. Eur. J. Cell Biol. 2003, 82, 53-73.
18. (a) Püschel, G.; Mentlein, R.; Heymann, E. Isolation and characterization of dipeptidyl peptidase IV from human placenta. Eur. J. Biochem. 1982, 126, 359-365.
19. (b) Heins, J.; Welker, P.; Schönlein, C.; Born, I.; Hartrodt, B.; Neubert, K.; Tsuru, D.; Barth, A. Mechanism of proline-specific proteinases: (I) substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim. Biophys. Acta 1988, 954, 161-169.
20. (c) Rahfeld, J.; Schutkowski, M.; Faust, J.; Neubert, K.; Barth, A.; Heins, J. Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biol. Chem. Hoppe-Seyler 1991, 372, 313-318.
21. Mentlein, R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85, 9-24.
22. (a) Deacon, C. F.; Nauck, M. A.; Meier, J.; Hücking, K.; Holst, J. J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000, 85, 3575-3581.
23. (b) Meier, J. J.; Nauck, M. A.; Schmidt, W. E.; Gallwitz, B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 2002, 107, 1-13.
24. (c) Vilsbøll, T.; Krarup, T.; Madsbad, S.; Holst, J. J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114, 115-121.
25. Hansotia, T.; Baggio, L.; Yamada, Y.; Tsukiyama, K.; Preitner, F.; Thorens, B.; Seino, Y.; Drucker, D. Combined genetic disruption of dual incretin receptor signaling pathways reveals novel glucose lowering properties of DPP-IV inhibitors in mice. Diabetes 2003, 52 (S1), A77.
26. Zhu, L.; Tamvakopoulos, C.; Xie, D.; Dragovic, J.; Shen, X.; Fenyk-Melody, J. E.; Schmidt, K.; Bagchi, A.; Griffin, P. R.; Thornberry, N. A.; Sinha Roy, R. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides. J. Biol. Chem. 2003, 278, 22418-22423.
27. Senten, K.; Daniëls, L.; Ven der Veken, P.; De Meester, I.; Lambeir, A. M.; Scharpé, S.; Haemers, A.; Augustyns, K. Rapid parallel synthesis of dipeptide diphenyl phosphonate esters as inhibitors of dipeptidyl peptidases. J. Comb. Chem. 2003, 5, 336-344.
28. Demuth, H. U.; Baumgrass, R.; Schaper, C.; Fischer, G.; Barth, A. Dipeptidyl peptidase IV-Inactivation with N-peptidyl-O-aryl hydroxylamines. J. Enzyme Inhib. 1988, 2, 129-142.
29. Snow, R. J.; Bachovchin, W. W. Boronic acid inhibitors of dipeptidyl peptidase IV: a new class of immunosuppressive agents. Adv. Med. Chem. 1995, 3, 149-177.
30. (a) Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D.; Jones, D. M.; Szelke, M. 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, 2745-2748.
31. (b) Augustyns, K. J. L.; Lambeir, A. M.; Borloo, M.; De Meester, I.; Vedernikova, I.; Vanhoof, G.; Hendriks, D.; Scharpé, S.; Haemers, A. Pyrrolidides: synthesis and structure-activity relationship as inhibitors of dipeptidyl peptidase IV. Eur. J. Med. Chem. 1997, 32, 301-309.
32. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D.; Jones, D. M.; Szelke, M. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, 1163-1166.
33. (a) Hughes, T. E.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Villhauer, E. B. (1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidylp peptidase IV. Biochemistry 1999, 38, 11597-11603.
34. (b) Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Hughes, T. E. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)- pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2002, 45, 2362-2365.
35. (c) Villhauer, E. B.; Brinkman, J. A.; Naderi, G.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46, 2774-2789.
36. Damon, R. Tetrahydroisoquinoline 3-carboxamide derivatives. U.S. 6,172,081, 2001.
37. (a) Schön, E.; Born, I.; Demuth, H. U.; Faust, J.; Neubert, K.; Steinmetzer, T.; Barth, A.; Ansorge, S. Dipeptidyl peptidase IV in the immune system. Biol. Chem. Hoppe-Seyler 1991, 372, 305-311.
38. (b) Stöckel-Maschek, A.; Mrestani-Klaus, C.; Stiebitz, B.; Demuth, H. U.; Neubert, K. Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. Biochim. Biophys. Acta 2000, 1479, 15-31.
39. Parmee, E. R.; He, J.; Mastracchio, A.; Edmondson, S. D.; Colwell, L.; Eiermann, G.; Feeney, W. P.; Habulihaz, B.; He, H.; Kilburn, R.; Leiting, B.; Lyons, K.; Marsilio, F.; Patel, R.; Petrov, A.; Di Salvo, J.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. 4-Amino cyclohexylglycine analogs as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 43-46.
40. Zhao, K.; Lim, D. S.; Funaki, T.; Welch, J. T. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidine)- cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg. Med. Chem. Lett. 2003, 11, 207-215.
41. (a) Himmelsbach, F.; Mark, M.; Eckhardt, M.; Langkopf, E.; Mater, R.; Lotz, R. Xanthine derivatives, production and use thereof as a medicament. WO02/068420, 2002.
42. (b) Branner, K. A.; Carr, R. D.; Christiansen, L. B.; Elm, T.; Ribel, U. A structurally novel dipeptidyl peptidase IV inhibitor: 7-benzyl-1,3-dimethyl-8- piperazinoxanthine. Presented at the 28th National Medicinal Chemistry Symposium, June 8-12, 2002; Abstract 72.
43. Coppola, G. M.; Zhang, Y. L.; Schuster, H. F.; Russell, M. E.; Hughes, T. E. 1-Aminomethylisoquinoline-4-carboxylates as novel dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 1555-1558.
44. Oi, S.; Ikedou, K.; Takeuchi, K.; Ogino, M.; Banno, Y.; Tawada, H.; Yamane, T. Fused heterocyclic compounds. WO02/062764, 2002.
45. (a) Rasmussen, H. B.; Branner, S.; Wiberg, F. C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol. 2003, 10, 19-25.
46. (b) Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.-U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5063-5068.
47. (c) Oefner, C.; D'Arcy, A.; Mac Sweeney, A.; Pierau, S.; Gardiner, R.; Dale, G. E. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[({2-[(5-iodopyridin-2-yl)amino]ethyl}amino)acetyl]-2- cyano-(S)-pyrrolidine. Acta Crystallogr. 2003, D59, 1206-1212.
48. (d) Thoma, R.; Löffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 2003, 11, 947-959.
49. (a) Rosenblum, J. S.; Kozarich, J. W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol. 2003, 7, 1-9.
50. (b) Šedo, A.; Malik, R. Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim. Biophys. Acta 2001, 1550, 107-116.
51. (c) Cunningham, D. F.; O'Connor, B. Proline specific peptidases. Biochim. Biophys. Acta 1997, 1343, 160-186.
52. Jones, B.; Adams, S.; Miller, G. T.; Jesson, M. I.; Watanabe, T.; Wallner, B. P. Hematopoietic stimulation by a peptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003, 102, 1641-1648.
53. Abbott, C. A.; Yu, D. M. T.; Woollatt, E.; Sutherland, G. R.; McCaughan, G. W.; Gorrell, M. D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 2000, 267, 6140-6150.
54. (a) Olsen, C.; Wagtmann, N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 2002, 299, 185-193.
55. (b) Qi, S. Y.; Riviere, P. J.; Trojnar, J.; Junien, J. L.; Akinsanya, K. O. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem. J. 2003, 373, 179-189.
56. Leiting, B.; Pryor, K. D.; Wu, J. K.; Marsilio, F.; Patel, R. A.; Craik, C. S.; Ellman, J. A.; Cummings, R. T. Thornberry, N. A. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J. 2003, 371, 525-532.
57. Underwood, R.; Chiravuri, M.; Lee, H.; Schmitz, T.; Kabcenell, A. K.; Yardley, K.; Huber, B. T. Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J. Biol. Chem. 1999, 274, 34053-34058.
58. Senten, K.; Van der Veken, P.; Bal, G.; De Meester, I.; Lambeir, A. M.; Scharpé, S.; Bauvois, B.; Haemers, A.; Augustyns, K. Development of Potent and Selective Dipeptidyl Peptidase II Inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 2825-2828.
59. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A.-M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6874-6879.
60. Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Yoshikawa, S.; Asano, O.; Tanaka, I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. 2001, 284, 501-506.
61. Ahrén, B.; Holst, J. J.; Mårtensson, H.; Balkan, B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 2000, 404, 239-245.
62. (a) Pederson, R. A.; White, H. A.; Schlenzig, D.; Pauly, R. P.; McIntosh, C. H.; Demuth, H.-U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998, 47, 1253-1258.
63. (b) Balkan, B.; Kwasnik, L.; Miserendino, R.; Holst, J. J.; Li, X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42, 1324-1331.
64. Nagakura, T.; Yasuda, N.; Yamazaki, K.; Ikuta, H.; Tanaka, I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 2003, 52, 81-86.
65. Pospisilik, J. A.; Stafford, S. G.; Demuth, H.-U.; McIntosh, C. H. S.; Pederson, R. A. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat. Diabetes 2002, 51, 2677-2683.
66. Pospisilik, J. A.; Stafford, S. G.; Demuth, H.-U.; Brownsey, R.; Parkhouse, W.; Finegood, D. T.; McIntosh, C. H. S.; Pederson, R. A. Long-term treatment with dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell responsiveness in VDF (fa/fa) Zucker rat. Diabetes 2002, 51, 943-950.
67. Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, D. M.; Haigh, R.; Junien, J.-L.; Aubert, M. L. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002, 51, 1461-1469
68. Reimer, M. K.; Holst, J. J.; Ahrén, B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur. J. Endocrinol. 2002, 146, 717-727.
69. Pospisilik, J. A.; Martin, J.; Doty, T.; Ehses, J. A.; Pamir, N.; Lynn, F. C.; Piteau, S.; Demuth, H.-U.; McIntosh, C. H. S.; Pederson, R. A. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52, 741-750.
70. (a) Sorbera, L. A.; Revel, L.; Castañer, J. P32/98: Antidiabetic dipeptidyl-peptidase IV inhibitor. Drugs Future 2001, 26, 859-864.
71. (b) Glund, K.; Hoffmann, T.; Demuth, H.-U.; Banke-Bochita, J.; Rost, K.-L.; Fuder, H. Single dose-escalation study to investigate the safety and tolerability of the DP IV inhibitor P32/98 in healthy volunteers. Exp. Clin. Endocrinol. Diabetes 2000, 108, 159.
72. (a) Demuth, H.-U.; Hoffmann, T.; Glund, K.; McIntosh, C. H. S.; Pederson, R. A.; Fuecker, K.; Fischer, S.; Hanefeld, M. Single Dose Treatment of Diabetic Patients by the DP IV Inhibitor P32/98. Diabetes 2000, 49 (S1), A102.
73. (b) Hoffmann, T.; Wolf, R.; Rosche, F.; Fischer, S.; Hanefeld, M.; Pederson, R. A.; McIntosh, D. H. S.; Glund, K.; Demuth, H.-U. Kinetics of active and inactive plasma GIP in type 2 diabetic patients during treatment with the DP IV-inhibitor P32/98: direct determination by immunoprecipitation LC-MS. Diabetes 2002, 51 (S2), A340.
74. Ahrén, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.-A.; Sandqvist, M.; Båvenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25, 869-875.
75. Ahrén, B.; Landin-Olsson, M.; Jansson, P.-A.; Eriksson, J.; Pacini, G.; Thomaseth, K.; Schweizer, A. The DPPIV inhibitor, LAF237, reduces fasting and postprandial glucose in subjects with type 2 diabetes over a 4 week period by increasing active GLP-1, sustaining insulin and reducing glucagon. Diabetes 2003, 52 (S1), A15.
76. Burkey, B. F.; Li, X.; Bolognese, L.; Russell, M.; Want, P. R.; Villhauer, E. B.; Hughes, T. E. Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats. Diabetes 2002, 51 (S2), A338-A339.
77. (a) Conarello, S. L.; Li, Z.; Ronan, J.; Sinha Roy, R.; Zhu, L.; Jiang, G.; Liu, F.; Woods, J.; Zycband, E.; Moller, D. E.; Thornberry, N. A.; Zhang, B. B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6825-6830.
78. (b) Yasuda, N.; Nagakura, T.; Yamazaki, K.; Inoue, T.; Tanaka, I. Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sci. 2002, 71, 227-238.
79. Lovshin, J.; Drucker, D. J. New frontiers in the biology of GLP-2. Regul. Pept. 2000, 90, 27-32.
80. (a) Shane, R.; Wilk, S.; Bodnar, R. J. Modulation of endomorphin-2- induced analgesia by dipeptidyl peptidase IV. Brain Res. 1999, 815, 278-286.
81. (b) Sakurada, C.; Sakurada, S.; Hayashi, T.; Katsuyama, S.; Tan-No, K.; Sakurada, T. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem. Pharmacol. 2003, 66, 653-661.
82. (a) Tanaka, S.; Murakami, T.; Horikawa, H.; Sugiura, M.; Kawashima, K.; Sugita, T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int. J. Immunopharmacol. 1997, 19, 15-24.
83. (b) Ohnuki, T.; Yamada, M.; Sugita, T. Novel dipeptidyl peptidase IV inhibitors with antiarthritic effects. Drugs Future 1999, 24, 665-670.
84. (a) De Meester, I.; Belyaev, A.; Lambeir, A. M.; De Meyer, G. R. Y.; Van Osselaer, N.; Haemers, A.; Scharpé, S. In vivo inhibition of dipeptidyl peptidase IV activity by Pro-Pro-diphenyl-phosphonate (Prodipine). Biochem. Pharmacol. 1997, 54, 173-179.
85. (b) Korom, S.; De Meester, I.; Stadlbauer, T. H. W.; Chandraker, A.; Schaub, M.; Sayegh, M. H.; Belyaev, A.; Haemers, A.; Scharpé, S.; Kupiec-Weglinski, J. W. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997, 63, 1495-1500.